App-Quantinova.ai

Beta-catenin nuclear translocation in colorectal cancer cells is suppressed by PDE10A inhibition, cGMP elevation, and activation of PKG

Kevin J. Lee - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

MP-10

Spliceosome inhibition as novel strategy against diffuse malignant peritoneal mesothelioma

Rocco Sciarrillo - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Title: IACS-010759 is a novel clinical candidate that targets AML cells by inducing a metabolic catastrophe through inhibition of oxidative phosphorylation

Jennifer R. Molina - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

IACS-010759

A novel small molecule inhibitor of the Notch transcription activation complex

Rajwinder Lehal - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

BGB-283, a slow-off inhibitor of RAF dimers, differentiates from vemurafenib in MAPK signaling inhibition

Ye Liu - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

selumetinib

Olive oil-based oleocanthal and bioisosteres as c-Met inhibitors for the control of triple negative breast cancer

Hassan Y. Ebrahim - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Development of an in vitro screening platform for high capacity evaluation of immunomodulatory drug candidates

Sujatha Kumar - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Development and characterization of an in vitro co-culture angiogenesis assay system using hTERT immortalized cells for high throughput drug screening

Chaozhong Zou - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Bevacizumab

Rapid harvesting of highly concentrated circulating tumor cells from bulk human blood with buoyant immuno-microbubbles

Guankui Wang - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

L-Tyrosine

A homogeneous bioluminescent succinate assay for detection of jumonjiC domain-containing histone demethylase activities

Juliano Alves - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Establishment of multicellular tumor spheroids-based assay for screening of novel therapeutics

Yeonhwa Song - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Validation of human osteoclast cultures for studying the mode-of-action and identification of new compounds with the potential of inhibiting the vicious cycle in osteolytic bone metastases

Jenni Bernoulli - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

MK-0822

Assessing the therapeutic efficacy of Cyst(e)inase to induce oxidative stress mediated cytotoxicity in pancreatic cancer cells

Sabin Kshattry - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

glutathione

The PI3K inhibitor, taselisib (GDC-0032), has enhanced potency in PIK3CA mutant models through a unique mechanism of action

Kyle A. Edgar - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Taselisib

Taselisib enhances the potency of ERBB inhibitors in biomarker-defined subsets of head and neck squamous carcinoma cell lines

Heidi M. Savage - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Taselisib

Exploring intermittent dosing schedules for the Pan PI3K/mTor inhibitor PQR309

Karin Jorga - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

PQR309

Concomitant administration of acid reducing agents can impact the pharmacokinetics of the balanced pan-PI3K and mTOR inhibitor PQR309

Karin Jorga - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Solid malignancies

PQR309

Pathway-directed high throughput drug screen identifies PI3K inhibitors that synergistically potentiate anti-tumor activity of HDAC inhibitors in mycosis fungoides and Sezary syndrome

Chen-Yen Yang - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Colorectal cancer pulmonary metastasis treatment with lung-selective delivery of PAN-class I PI3K inhibitors

Piotr Rychahou - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Phosphatidylinositol

Implications of Akt inhibition for neoadjuvant radiotherapy: improving the rectal cancer treatment

Fernanda C. Koyama - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Phosphatidylinositol

Filters

41730 Abstracts